1AD.AU · AdAlta Limited

-

Please sign in to comment on 1AD.AU

1 Comment

Admin

4 years, 1 month ago

AdAlta Limited is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.

From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 44.8.

AdAlta Limited's total revenue rose by 99.5% to $806K since the same quarter in the previous year.

Its net income has increased by 24.9% to $-5M since the same quarter in the previous year.

Finally, its free cash flow grew by 74.5% to $-399K since the same quarter in the previous year.

Based on the above factors, AdAlta Limited gets an overall score of 4/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU0000001AD2
Sector	Healthcare
Industry	Biotechnology

Market Cap	3M
PE Ratio	None
Target Price	None
Beta	0.2
Dividend Yield	None

ABOUT

AdAlta Limited

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor. The company was incorporated in 2006 and is based in Bundoora, Australia.

1AD.AU · AdAlta Limited

-

AdAlta Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest AdAlta Limited using a moving average strategy